Vir Biotechnology (VIR) Receivables (2020 - 2022)

Vir Biotechnology (VIR) posted Receivables of $7.0 million for Q2 2022, down 99.43% sequentially from $1.2 billion in Q1 2022.

Vir Biotechnology (VIR) Receivables (2020 - 2022) Analysis & Trends

Vir Biotechnology has reported Receivables for 3 years, with the latest figure at $7.0 million in Q2 2022.

Quarterly Receivables changed N/A year-over-year to $7.0 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $7.0 million (changed N/A YoY) and the FY2021 annual result came in at $773.1 million, changed N/A from the prior year.
Receivables declined to $7.0 million in Q2 2022 per VIR's latest filing, from $1.2 billion in the prior quarter.
Over five years, Receivables peaked at $1.2 billion in Q1 2022 and troughed at $3.8 million in Q2 2020.
A 3-year average of $387.5 million and a median of $159.0 million in 2021 frame the typical range for Receivables.
The widest YoY moves for Receivables: up 443.63% in 2022, down 443.63% in 2022.
Over 3 years, Receivables stood at $3.8 million in 2020, then jumped by 20244.18% to $773.1 million in 2021, then plunged by 99.09% to $7.0 million in 2022.
According to Business Quant data, Receivables over the past three periods registered $7.0 million, $1.2 billion, and $773.1 million for Q2 2022, Q1 2022, and Q4 2021 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	Vir Biotechnology	1.56 Bn	1.56 Bn	238.95 Mn	-

Download Data